Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gynecologic 1Endocrine 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Filgrastim 3Doxorubicin 3Temozolomide 2Octreotide 2Ifosfamide 2Etoposide 2Cisplatin 2Capecitabine 2vatalanib 1vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1telotristat ethyl 1pegfilgrastim 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lanreotide 1batifiban 1Suramin 1Radiotherapy 1Platinum 1Mitotane 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Everolimus 1Ethane 1Docetaxel 1Dichlorodiphenyldichloroethane 1DNA Methylation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × motesanib diphosphate × Endocrine × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡